These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37190983)

  • 21. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
    Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
    Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
    Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
    Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis.
    Xiong L; Cai Y; Zhou X; Dai P; Wei Y; Zhao J; Tang H
    Future Oncol; 2022 Mar; 18(7):883-896. PubMed ID: 34825576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
    Yoon HH; Shi Q; Ajani JA
    JAMA Oncol; 2023 Feb; 9(2):280-281. PubMed ID: 36547945
    [No Abstract]   [Full Text] [Related]  

  • 28. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
    Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
    Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
    Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab for the treatment of advanced esophageal cancer.
    Harada K; Yamamoto S; Kato K
    Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis.
    Beshr MS; Beshr IA; Al Hayek M; Alfaqaih SM; Abuajamieh M; Basheer E; Wali AK; Ekreer M; Chenfouh I; Khashan A; Hassan ET; Elnaami SM; Elhadi M
    Clin Oncol (R Coll Radiol); 2024 Dec; 36(12):797-808. PubMed ID: 39384455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
    Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
    BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
    Di Federico A; De Giglio A; Nuvola G; Deiana C; Conci N; Gelsomino F; Ardizzoni A
    Future Oncol; 2021 Nov; 17(32):4415-4424. PubMed ID: 34402681
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
    J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of the CD4
    Xu S; Zhu Q; Wu L; Wang Y; Wang J; Zhu L; Zheng S; Hang J
    Int Immunopharmacol; 2023 Oct; 123():110642. PubMed ID: 37499395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials.
    Gu L; Huang T; Qiu S; Hong J; Fu R; Ni C; Dai S; Chen P; He N
    Front Pharmacol; 2022; 13():1009254. PubMed ID: 36386140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.